IFNß Is a Potent Adjuvant for Cancer Vaccination Strategies.
Front Immunol
; 12: 735133, 2021.
Article
de En
| MEDLINE
| ID: mdl-34552594
ABSTRACT
Cancer vaccination drives the generation of anti-tumor T cell immunity and can be enhanced by the inclusion of effective immune adjuvants such as type I interferons (IFNs). Whilst type I IFNs have been shown to promote cross-priming of T cells, the role of individual subtypes remains unclear. Here we systematically compared the capacity of distinct type I IFN subtypes to enhance T cell responses to a whole-cell vaccination strategy in a pre-clinical murine model. We show that vaccination in combination with IFNß induces significantly greater expansion of tumor-specific CD8+ T cells than the other type I IFN subtypes tested. Optimal expansion was dependent on the presence of XCR1+ dendritic cells, CD4+ T cells, and CD40/CD40L signaling. Therapeutically, vaccination with IFNß delayed tumor progression when compared to vaccination without IFN. When vaccinated in combination with anti-PD-L1 checkpoint blockade therapy (CPB), the inclusion of IFNß associated with more mice experiencing complete regression and a trend in increased overall survival. This work demonstrates the potent adjuvant activity of IFNß, highlighting its potential to enhance cancer vaccination strategies alone and in combination with CPB.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs cutanées
/
Mélanome expérimental
/
Activation des lymphocytes
/
Adjuvants immunologiques
/
Lymphocytes TIL
/
Interféron bêta
/
Lymphocytes T CD8/
/
Vaccins anticancéreux
Limites:
Animals
Langue:
En
Journal:
Front Immunol
Année:
2021
Type de document:
Article
Pays d'affiliation:
Australie